SPONSORED CONTENT

ISSAR Pharma announces out-licensing of its Peptide-based NCEs

April 29, 2021 14:01 IST | ANI Press Release
Tennis player James Blake
ISSAR Pharma

Hyderabad (Telangana) [India], April 29 (ANI/PNN): ISSAR Pharmaceuticals, pioneers in Peptide Technology and peptide drug innovation, has decided to license out their peptide-based New Chemical Entities (NCEs), with pre-IND filing and US patent.

The potential collaboration would help ISSAR Pharmaceuticals in their goal to design and deliver novel peptide-based drugs for various unmet healthcare needs of the population and making them affordable and accessible for better health outcomes.

ISSAR Pharmaceuticals exclusively focuses on peptide technology-based research and development of New Chemical Entities (NCE) for various unmet medical needs to improve the quality of life. ISSAR uses solid-phase peptide synthesis as the technology of choice and has the capability to synthesize custom peptides, API peptides and cosmetic peptides at all scales within a short duration. With an emphasis on quality, safety, and innovation, ISSAR has demonstrated the ability to move products from conceptualisation to commercialisation of peptide molecules at all stages. ISSAR has several patents for potential life-changing peptide molecules lined up in their development pipeline targeting therapeutic areas such as oncology, dermatology, gastroenterology, and diseases of bones and joints.

"We take pride in being India's first-ever company to conduct phase-1 clinical trials and launch the first-ever indigenous peptide drug, Melgain in the market for the treatment of Vitiligo in 2004", informs Ramakrishna Reddy Isanaka, the founder of ISSAR.

FDA-compliant state-of-the-art manufacturing facility of 62000 sq. ft. is purely into peptide manufacturing technology, located in Genome Valley, Hyderabad. In addition to its experience in R & D, ISSAR is equipped with the most advanced and automatic technology with expertise in the synthesis and purification of peptides, producing the highest standards of purity of up to 99.5 per cent by continued process optimisation.

With over 25 years of experience and a prime focus in Research and Development, ISSAR's dedicated team of experts is proud to have developed India's first-ever peptide molecule, Melgain for the treatment of Vitiligo in 2004, which is now introduced as Novoskin® with improved properties and effectiveness. ISSAR's commitment has also led to the development of their second new chemical entity called Xylentra, which is the first-ever peptide drug in the world for the treatment of burn wounds and microbial infections.

ISSAR developed molecules for prevalent conditions in the western world such as Inflammatory Bowel Diseases (IBD), Psoriasis, and Sepsis. Recently, an NCE for the treatment of burn wounds (Xylentra) was licensed to Viatris, formerly known as Mylan Laboratories, the USA in 2020.

ISSAR Pharmaceuticals was founded by Ramakrishna Reddy Isanaka in 1995 with a vision to be a global leader in peptide drug discovery for improving patients' quality of life. Before starting ISSAR Pharmaceutical, Isanaka was the promoter and director of Shantha Biotechnics in the 1980s, at a time when biotechnology was new to India.

His efforts in research and development led to the advancement of ISSAR Pharma as the first-ever company in India to conduct Phase-I clinical trials in the year 1995. Today, he has over 25 years of experience in the development of NCEs with two successfully commercialized products, seven plus patents to his credit, and over 6 commercially viable products under development.

(https://issar.co.in)

This story is provided by PNN. ANI will not be responsible in any way for the content of this article. (ANI/PNN)

DISCLAIMER


(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

 

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

ISSAR Pharma announces out-licensing of its Peptide-based NCEs

Hyderabad (Telangana) [India], April 29 (ANI/PNN): ISSAR Pharmaceuticals, pioneers in Peptide Technology and peptide drug innovation, has decided to license out their peptide-based New Chemical Entities (NCEs), with pre-IND filing and US patent.

The potential collaboration would help ISSAR Pharmaceuticals in their goal to design and deliver novel peptide-based drugs for various unmet healthcare needs of the population and making them affordable and accessible for better health outcomes.

ISSAR Pharmaceuticals exclusively focuses on peptide technology-based research and development of New Chemical Entities (NCE) for various unmet medical needs to improve the quality of life. ISSAR uses solid-phase peptide synthesis as the technology of choice and has the capability to synthesize custom peptides, API peptides and cosmetic peptides at all scales within a short duration. With an emphasis on quality, safety, and innovation, ISSAR has demonstrated the ability to move products from conceptualisation to commercialisation of peptide molecules at all stages. ISSAR has several patents for potential life-changing peptide molecules lined up in their development pipeline targeting therapeutic areas such as oncology, dermatology, gastroenterology, and diseases of bones and joints.

"We take pride in being India's first-ever company to conduct phase-1 clinical trials and launch the first-ever indigenous peptide drug, Melgain in the market for the treatment of Vitiligo in 2004", informs Ramakrishna Reddy Isanaka, the founder of ISSAR.

FDA-compliant state-of-the-art manufacturing facility of 62000 sq. ft. is purely into peptide manufacturing technology, located in Genome Valley, Hyderabad. In addition to its experience in R & D, ISSAR is equipped with the most advanced and automatic technology with expertise in the synthesis and purification of peptides, producing the highest standards of purity of up to 99.5 per cent by continued process optimisation.

With over 25 years of experience and a prime focus in Research and Development, ISSAR's dedicated team of experts is proud to have developed India's first-ever peptide molecule, Melgain for the treatment of Vitiligo in 2004, which is now introduced as Novoskin® with improved properties and effectiveness. ISSAR's commitment has also led to the development of their second new chemical entity called Xylentra, which is the first-ever peptide drug in the world for the treatment of burn wounds and microbial infections.

ISSAR developed molecules for prevalent conditions in the western world such as Inflammatory Bowel Diseases (IBD), Psoriasis, and Sepsis. Recently, an NCE for the treatment of burn wounds (Xylentra) was licensed to Viatris, formerly known as Mylan Laboratories, the USA in 2020.

ISSAR Pharmaceuticals was founded by Ramakrishna Reddy Isanaka in 1995 with a vision to be a global leader in peptide drug discovery for improving patients' quality of life. Before starting ISSAR Pharmaceutical, Isanaka was the promoter and director of Shantha Biotechnics in the 1980s, at a time when biotechnology was new to India.

His efforts in research and development led to the advancement of ISSAR Pharma as the first-ever company in India to conduct Phase-I clinical trials in the year 1995. Today, he has over 25 years of experience in the development of NCEs with two successfully commercialized products, seven plus patents to his credit, and over 6 commercially viable products under development.

(https://issar.co.in)

This story is provided by PNN. ANI will not be responsible in any way for the content of this article. (ANI/PNN)

DISCLAIMER


(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22